Literature DB >> 21775914

Clinical significance of portal-superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head cancer.

Sung-Sik Han1, Sang-Jae Park, Seong Hoon Kim, Seong Yeon Cho, Young-Kyu Kim, Tae Hyun Kim, Soon-ae Lee, Sang Myung Woo, Woo Jin Lee, Eun Kyung Hong.   

Abstract

OBJECTIVES: The purpose of this study was to determine the significance of portal vein-superior mesenteric vein (PV-SMV) invasion on survival in patients who underwent margin-negative pancreatoduodenectomy (PD) with PV-SMV resection for pancreatic adenocarcinoma.
METHODS: We retrospectively reviewed the records of 60 patients who underwent margin-negative PD with or without PV-SMV resection for pancreatic adenocarcinoma between August 2001 and December 2007. The depth of vessel invasion was investigated and was categorized into 3 groups: tunica adventitia, media, and intima. Clinicopathologic factors and survival were analyzed.
RESULTS: Portal vein-superior mesenteric vein resection was performed on 19 patients, but only 15 patients (78.9%) had histologically true invasion and showed poorer survival (median survival, 14 vs 9 months; P < 0.05). Univariate analysis revealed that poorly differentiated tumor, lymphatic invasion, endovascular invasion, PV-SMV invasion, and invasion into the intima of PV-SMV were statistically significant. Poorly differentiated tumor and invasion into the intima of PV-SMV were significant in multivariate analysis.
CONCLUSIONS: Aggressive surgical resection should be attempted in cases with suspected PV-SMV invasion because 21.1% of patients had no true invasion and showed better survival than those with true invasion. However, invasion into the tunica intima may be a poor prognostic factor for survival even after margin-negative PD for pancreatic adenocarcinoma.

Entities:  

Mesh:

Year:  2012        PMID: 21775914     DOI: 10.1097/MPA.0b013e318221c595

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

1.  The concept of 'borderline resectable' pancreatic cancer: limited foundations and limited future?

Authors:  John A Windsor; Savio George Barreto
Journal:  J Gastrointest Oncol       Date:  2017-02

Review 2.  Histopathologic tumor invasion of superior mesenteric vein/ portal vein is a poor prognostic indicator in patients with pancreatic ductal adenocarcinoma: results from a systematic review and meta-analysis.

Authors:  Ailin Song; Farong Liu; Lupeng Wu; Xiaoying Si; Yanming Zhou
Journal:  Oncotarget       Date:  2017-05-16

3.  Superior mesenteric artery margin in pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Dao-Ning Liu; Ang Lv; Zhi-Hua Tian; Xiu-Yun Tian; Xiao-Ya Guan; Bin Dong; Min Zhao; Chun-Yi Hao
Journal:  Oncotarget       Date:  2017-01-31

4.  Feasibility of portal or superior mesenteric vein resection and reconstruction by allogeneic vein for pancreatic head cancer-a case-control study.

Authors:  Xing-Mao Zhang; Jie Zhang; Hua Fan; Qiang He; Ren Lang
Journal:  BMC Gastroenterol       Date:  2018-04-16       Impact factor: 3.067

5.  Pancreatoduodenectomy with portal vein resection favors the survival time of patients with pancreatic ductal adenocarcinoma: A propensity score matching analysis.

Authors:  Zhi-Bo Xie; Ji Li; Ji-Chun Gu; Chen Jin; Cai-Feng Zou; De-Liang Fu
Journal:  Oncol Lett       Date:  2019-09-06       Impact factor: 2.967

6.  Unusual case of left-sided portal hypertension induced variceal bleeding after pancreaticoduodenectomy treated with transplenic embolization.

Authors:  Jia-An Hong; Chien-An Liu; Rheun-Chuan Lee; Nai-Chi Chiu; Hsuen-En Hwang
Journal:  Radiol Case Rep       Date:  2021-06-08

Review 7.  What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact?

Authors:  Julie Navez; Christelle Bouchart; Diane Lorenzo; Maria Antonietta Bali; Jean Closset; Jean-Luc van Laethem
Journal:  Ann Surg Oncol       Date:  2021-01-21       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.